Eli Lilly (NYSE:LLY) announced an expansion of its LillyDirect digital healthcare platform to facilitate contact with ...

Eli Lilly announced an expansion of its LillyDirect digital healthcare platform to facilitate contact with healthcare providers for Alzheimer's patients—providing a targeted solution for timely ...

Circular Genomics recently moved its headquarters to Lilly Gateway Labs, aiming to enhance its Alzheimer's disease ...

Jaypirca and Omvoh should also contribute meaningfully through the end of the decade. In other words, Eli Lilly's revenue should continue growing at a good clip. The midpoint of the company's ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly and Company (NYSE:LLY) offers a quarterly dividend of $1.50 per share and has a dividend yield of 0.71%, as of March 20. It is one of the best dividend stocks on our list as the company has ...

2. Omvoh: Recently approved for Crohn’s disease, expanding Eli Lilly’s presence in the inflammatory bowel disease (IBD) space. 3. Ebglyss: Approved for atopic dermatitis, further diversifying ...

as well as approval for Omvoh for managing moderately to severely active Crohn’s disease. Eli Lilly and Company (NYSE:LLY)’s rapid growth in recent years has been largely fueled by the success ...

Eli Lilly and Company discovers ... and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized ...